Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Akebia Therapeutics Inc (NASDAQ: AKBA) was $1.92 for the day, up 3.50% from the previous closing price of $1.86. In other words, the price has increased by $3.50 from its previous closing price. On the day, 2.16 million shares were traded.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.52.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.47.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is -4.42%, while the 200-Day Moving Average is calculated to be 22.09%.
Shares Statistics:
A total of 211.54M shares are outstanding, with a floating share count of 209.50M. Insiders hold about 3.98% of the company’s shares, while institutions hold 28.71% stake in the company.
